Data from Initial Patient Cohorts of Phase 2 AFFINITY Study Expected to be Reported in 2022

Follow this link:

Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh